1
|
Chaaban S, Istvan M, Schreck B, Laigo P, Rousselet M, Grall-Bronnec M, Pain S, Victorri-Vigneau C. Cannabis use and dependence among festival attendees: results from the French OCTOPUS survey. BMC Public Health 2024; 24:992. [PMID: 38594675 PMCID: PMC11003156 DOI: 10.1186/s12889-024-18496-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 04/01/2024] [Indexed: 04/11/2024] Open
Abstract
BACKGROUND Chronic use of cannabis is associated with an increased risk of psychosocial, mental and physical health impairments. Sociohealth institutions reach a very limited proportion of cannabis users in need of treatment. Using data collected from festival attendees, this study aimed to estimate the prevalence of dependent cannabis users and to characterize cannabis dependence. METHODS We used data from the cross-sectional OCTOPUS survey carried out at 13 music events in the French department of Loire-Atlantique between July 2017 and July 2018. 383 participants aged 18 or older underwent a face-to-face interview about their basic sociodemographics, tobacco use, alcohol use and past-year substance use. Using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, we estimated the prevalence of dependent cannabis users and characterized their dependence. RESULTS More than two-thirds of participants reported that they had used cannabis in the past 12 months. Among 194 regular cannabis users (at least monthly), 63.4% were dependent. At least 40% of regular users reported health and/or social consequences of cannabis use. Compared to nondependent cannabis users, dependent cannabis users were more likely to be stimulant users and hallucinogen users. CONCLUSIONS Dependent cannabis use is common among festival attendees, especially among stimulant or hallucinogen users. Festival settings may be important arenas for i) implementing efficient harm reduction measures to prevent dependence and ii) providing information on care structures and promoting the use of care to dependent users. In addition, healthcare professionals should be aware of trends in polysubstance use among dependent cannabis users.
Collapse
Affiliation(s)
- Sarah Chaaban
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Marion Istvan
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
| | - Benoit Schreck
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Pauline Laigo
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Morgane Rousselet
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France.
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France.
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France.
| | - Marie Grall-Bronnec
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
- UIC Psychiatrie et Santé Mentale, Nantes Université, CHU Nantes, F-44000, Nantes, France
| | - Stéphanie Pain
- Centre d'addictovigilance, Service de Pharmacologie Clinique, CHU de Poitiers, 86000, Poitiers, France
- Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM U-1084, Université de Poitiers, 86000, Poitiers, France
| | - Caroline Victorri-Vigneau
- Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, CHU Nantes, F-44000, Nantes, France
- Nantes Université, Univ Tours, CHU Nantes, CHU Tours, INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, F-44000, Nantes, France
| |
Collapse
|
3
|
Rousselet M, Feuillet F, Gerardin M, Jolliet P, Hardouin JB, Victorri-Vigneau C. The French addictovigilance network clinical assessment: Z-drugs, true false twins. Expert Opin Drug Saf 2017. [PMID: 28649864 DOI: 10.1080/14740338.2017.1346084] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION In France, an addictovigilance network is responsible for evaluating drug dependence, by drawing on pharmacoepidemiological studies, clinical studies and by assessing healthcare professionals' reports on problematic consumption. METHODS The aim of this study was to determine whether zolpidem and zopiclone have different dependence profiles, based on healthcare professionals' reports, and to identify various consumer dependence profiles among zolpidem users and among zopiclone users. Dependence in reports was assessed using the EGAP scale; a scale developed using the DSM diagnostic dependence criteria. RESULTS The comparison of dependence profiles for zolpidem and zopiclone showed differences both in total EGAP score and EGAP item positivity. The descriptive analysis showed that EGAP scores were higher for zolpidem than for zopiclone, suggesting more severe problematic consumption with zolpidem. For zolpidem 2 subpopulations of consumers were identified, with one subpopulation's consumption being more severe than the other, with a significantly higher total EGAP score and more harmful consequences. No subpopulation was highlighted for zopiclone. CONCLUSION These results were in favour of a higher prevalence of physical and compulsive signs of dependence and of harmful consequences of dependence, with zolpidem than with zopiclone.
Collapse
Affiliation(s)
- Morgane Rousselet
- a Centre for Evaluation and Information on Pharmacodependence - Addictovigilance , Clinical Pharmacology Department, University Hospital , Nantes , France.,b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France.,c Addictology and Psychiatry Department , University Hospital , Nantes , France
| | - Fanny Feuillet
- b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France
| | - Marie Gerardin
- a Centre for Evaluation and Information on Pharmacodependence - Addictovigilance , Clinical Pharmacology Department, University Hospital , Nantes , France.,b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France
| | - Pascale Jolliet
- a Centre for Evaluation and Information on Pharmacodependence - Addictovigilance , Clinical Pharmacology Department, University Hospital , Nantes , France.,b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France
| | - Jean-Benoit Hardouin
- b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France
| | - Caroline Victorri-Vigneau
- a Centre for Evaluation and Information on Pharmacodependence - Addictovigilance , Clinical Pharmacology Department, University Hospital , Nantes , France.,b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France
| |
Collapse
|
5
|
Victorri-Vigneau C, Hardouin JB, Rousselet M, Gerardin M, Guerlais M, Guillou M, Bronnec M, Sébille V, Jolliet P. Multicentre study for validation of the French addictovigilance network reports assessment tool. Br J Clin Pharmacol 2016; 82:1030-9. [PMID: 27302554 DOI: 10.1111/bcp.13044] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 06/06/2016] [Accepted: 06/09/2016] [Indexed: 11/27/2022] Open
Abstract
AIMS The French health authority (ANSM) is responsible for monitoring medicinal and other drug dependencies. To support these activities, the ANSM manages a network of 13 drug dependence evaluation and information centres (Centres d'Evaluation et d'Information sur la Pharmacodépendance - Addictovigilance - CEIP-A) throughout France. In 2006, the Nantes CEIP-A created a new tool called the EGAP (Echelle de GrAvité de la Pharmacodépendance- drug dependence severity scale) based on DSM IV criteria. This tool allows the creation of a substance use profile that enables the drug dependence severity to be homogeneously quantified by assigning a score to each substance indicated in the reports from health professionals. This article describes the validation and psychometric properties of the drug dependence severity score obtained from the scale ( Clinicaltrials.gov NCT01052675). METHOD The validity of the EGAP construct, the concurrent validity and the discriminative ability of the EGAP score, the consistency of answers to EGAP items, the internal consistency and inter rater reliability of the EGAP score were assessed using statistical methods that are generally used for psychometric tests. RESULTS The total EGAP score was a reliable and precise measure for evaluating drug dependence (Cronbach alpha = 0.84; ASI correlation = 0.70; global ICC = 0.92). In addition to its good psychometric properties, the EGAP is a simple and efficient tool that can be easily specified on the official ANSM notification form. CONCLUSION The good psychometric properties of the total EGAP score justify its use for evaluating the severity of drug dependence.
Collapse
Affiliation(s)
- Caroline Victorri-Vigneau
- Pharmacology Department, Nantes University Hospital, Institute of Biology, Hôtel Dieu, 9, Quai Moncousu, 44093, Nantes Cedex 01, France. .,EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France.
| | - Jean Benoit Hardouin
- EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France
| | - Morgane Rousselet
- Pharmacology Department, Nantes University Hospital, Institute of Biology, Hôtel Dieu, 9, Quai Moncousu, 44093, Nantes Cedex 01, France.,EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France.,Addictology Department, Nantes University Hospital, Bâtiment Louis Philippe, Hôpital St Jacques, 85 rue Saint-Jacques, 44093, Nantes Cedex 1, France
| | - Marie Gerardin
- Pharmacology Department, Nantes University Hospital, Institute of Biology, Hôtel Dieu, 9, Quai Moncousu, 44093, Nantes Cedex 01, France.,EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France
| | - Marylène Guerlais
- Pharmacology Department, Nantes University Hospital, Institute of Biology, Hôtel Dieu, 9, Quai Moncousu, 44093, Nantes Cedex 01, France
| | - Morgane Guillou
- Addictology Department, Nantes University Hospital, Bâtiment Louis Philippe, Hôpital St Jacques, 85 rue Saint-Jacques, 44093, Nantes Cedex 1, France
| | - Marie Bronnec
- EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France.,Addictology Department, Nantes University Hospital, Bâtiment Louis Philippe, Hôpital St Jacques, 85 rue Saint-Jacques, 44093, Nantes Cedex 1, France
| | - Véronique Sébille
- EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France
| | - Pascale Jolliet
- Pharmacology Department, Nantes University Hospital, Institute of Biology, Hôtel Dieu, 9, Quai Moncousu, 44093, Nantes Cedex 01, France.,EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences, 1 rue Gaston Veil, BP 53508, 44035, Nantes cedex 1, France
| | | |
Collapse
|